MVI Vaccine to Be Used in Clinical Trial of a New Combination Approach to Immunotherapy Funded by the Prostate Cancer Foundation and the Movember Foundation

Trial Pairs MVI-816 with a PD-1 Pathway Inhibitor to Treat Metastatic Prostate Cancer Prostate Cancer Foundation/Movember Foundation Award Goes to the University of Wisconsin to Conduct the Clinical Trial August 27, 2014 Madison Vaccines Incorporated (MVI), a clinical stage biopharmaceutical company, today said its lead product candidate MVI-816 (pTVG-HP) will be used in a clinical trial testing a two-pronged immunotherapy …

Madison Vaccines Incorporated Announces Expansion of a Phase 2 Clinical Trial for MVI-816, Its Lead DNA Vaccine for Prostate Cancer

MVI-816 Intended to Delay Metastatic Disease after Primary Therapy, but Before Hormonal Therapy Trial Now Enrolling at University of Wisconsin, with Additional Centers to Follow June 23, 2014 Madison Vaccines Incorporated (MVI), a clinical stage biopharmaceutical company, today announced enrollment has begun in the expansion of a Phase 2 clinical trial of its lead product candidate MVI-816 (pTVG-HP). The expansion …